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Abstract
Background: Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune
adjuvant therapy with recombinant interferon-c1b (rIFN-cb) may reduce pulmonary inflammation and reduce the period of
infectivity by promoting earlier sputum clearance.
Methodology/Principal Findings: We performed a randomized, controlled clinical trial of directly observed therapy (DOTS)
versus DOTS supplemented with nebulized or subcutaneously administered rIFN-c1b over 4 months to 89 patients with
cavitary pulmonary tuberculosis. Bronchoalveolar lavage (BAL) and blood were sampled at 0 and 4 months. There was a
significant decline in levels of inflammatory cytokines IL-1b, IL-6, IL-8, and IL-10 in 24-hour BAL supernatants only in the
nebulized rIFN-c1b group from baseline to week 16. Both rIFN-c1b groups showed significant 3-fold increases in CD4+
lymphocyte response to PPD at 4 weeks. There was a significant (p=0.03) difference in the rate of clearance of Mtb from the
sputum smear at 4 weeks for the nebulized rIFN-c1b adjuvant group compared to DOTS or DOTS with subcutaneous rIFN-
c1b. In addition, there was significant reduction in the prevalence of fever, wheeze, and night sweats at 4 weeks among
patients receiving rFN-c1b versus DOTS alone.
Conclusion: Recombinant interferon-c1b adjuvant therapy plus DOTS in cavitary pulmonary tuberculosis can reduce
inflammatory cytokines at the site of disease, improve clearance of Mtb from the sputum, and improve constitutional
symptoms.
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Introduction
Mycobacterium tuberculosis (Mtb) infects one-third of the world’s
population, resulting in 9.2 million active cases per year [1]. Since
the Directly Observed Therapy (Isoniazid, Rifampin, Pyrazin-
amide, Ethambutol 6 month Short Course, DOTS) approach is
highly successful, the World Health Organization has set the goal
of achieving 85% adherence, and the Global Plan to Stop TB has
a vision of halving the prevalence and mortality of tuberculosis by
2015 [2]. Transgenic knockout models of mycobacteria-exposed
mice demonstrate that interferon-c and its signaling intermediates
are critical to host defense [3,4]. In humans, mutational defects in
the interferon-c receptor, the cytokine IL-12, or antibodies to
interferon-c result in disseminated mycobacterial infection [5,6].
Sputum culture positive at two months, cavitation on chest
radiography, being underweight, and bilateral pulmonary involve-
ment increases the risk of treatment failure and/or relapse [7].
Responses of whole blood PBMC to PPD and other mycobacterial
antigens are reduced in active tuberculosis probably due to
suppressor T cells (Tregs ) or cytokines, e.g. IL-10 or TGF-b [8,9].
Bronchoalveolar lavage (BAL) of patients with pulmonary
tuberculosis has shown increases in inflammatory cytokines and
percent CD4+ cells compared to uninfected controls, and in
advanced, cavitary tuberculosis markers of effective immunity are
reduced. Nitric oxide (NO) has been identified as a mechanism of
mycobacterial killing, while mycobacteria can also be eliminated
by autophagy, apoptosis, cytotoxic CD8+ cells, alpha defensins
from neutrophils, and phagosomal-lysosomal rupture with subse-
quent cytosolic demise [10,11,12]. However, mycobacteria have
evolved virulence factors to persist in macrophages, possibly
disrupting the interferon-c signaling pathways. We hypothesized
that pharmacologic doses of rIFN-c1b could augment the host
immune response in TB, and to evaluate this we conducted a 4-
month randomized, controlled clinical trial with rIFN-c1b at
200 mg/day for three days/week with three arms: nebulized rIFN-
c1b or subcutaneous rIFN-c1b with DOTS versus DOTS alone.
End points were:: BAL cytokine release, treatment failure, sputum
smear and culture conversion, and respiratory and systemic
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e6984symptoms. We evaluated BAL cytokines,, mycobacterial and
clinical response, immunological outcomes, and postulate mech-
anisms that rIFN-c1b augmented to achieve an improved
outcome.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study Subjects
Patients with pulmonary tuberculosis were recruited from April
2005 to December 2006 in the Division of Pulmonology at the
University of Cape Town with the following inclusion criteria:
sputum smear and culture positive for Mycobacterium tuberculosis,a n d
bilateral cavitary tuberculosis. We randomized 96 patients who met
the entrance criteria. Four of these individuals grew Mtb (BACTEC
method) resistant to both isoniazid and rifampin and were thus
ineligible due to MDR-TB, two patients had negative cultures for
Mtb, and one patient had received a streptomycin-containing
regimen. They had been randomized with 4 subjects in the DOTS
plus subcutaneous IFN-c, 2 in the DOTS alone group, and 1 in the
DOTS plus nebulized IFN-c group. All of the remaining 89 patients
had Mtb cultured from their sputum and were drug-sensitive.
Respiratory symptoms (cough, wheeze, dyspnea grade 2 or 3, sputum
volume ,10 ml) and night sweats (number/week) were reviewed at
baseline and weekly during treatment by a blinded interviewer; oral
temperature (fever defined as 38.5 uC) was recorded by the study
nurse 3 times/week. IRB approval was obtained at NYU School of
Medicine and the University of Cape Town; all study subjects signed
informed consent in their native language. rIFN-c1b (recombinant,
InterMune Brisbane, CA) was nebulized with an AeroEclipse breath-
activated nebulizer (which improves alveolar deposition), or was
administered subcutaneously at 200 micrograms (excipient normal
saline) three times per week over 4 months. All patients had weekly
sputum smear and culture to 4 months and were followed up at 12
months with sputum smear and culture.
Bronchoalveolar lavage
Bronchoalveolar lavage was performed at baseline and 4 months.
Briefly, after local anesthesia with lidocaine, the bronchoscope was
inserted via the nasal passage to the lower respiratory tract, wedged,
and a 300-ml lavage was performed using 5, 20-ml aliquots of
normal saline in each of three involved lung segments. The
recoveredfluidwaspooled and filteredoversterilegauze,and atotal
cell count performed. A cytospin slide was stained with Diff-Quik
and 500 cells counted to determine the cell differential. BAL
supernatants were collected in RPMI over 24 hours at 10
6 BAL
cells/ml. Cytokines IL-1b, IL-6, IL-8, TNF-a, and IL-10 were
measured by Luminex Beadlyte ELISA assay. Immunoblots for C/
EBPb were done as previously described [13,14,15].
Systemic Response
Peripheral blood was obtained between 3–5 weeks for in vitro
stimulation. Mononuclear cells (PBMC) isolated by Ficoll-Paque
were cultured for 5 days in the absence or presence of
staphylococcal enterotoxin B, Mumps antigen, or PPD and pulsed
with BrDU during the last 24 hr. Cells were labeled with PerCP-
Cy5.5-anti-CD4 and allophycocyanin-anti-CD25, fixed and per-
meabilized, then labeled with FITC-anti-BrDU in the presence of
DNase I. Labeled cells were analyzed on a FACSCalibur, and
lymphoblasts displaying PerCP-Cy5.5 were identified as CD4+.
Proliferating cells were detected as CD25+BrDU+ lymphoblasts.
The proliferation index is given by the %CD25+BrDU+lympho-
blasts normalized by the %lymphoblast-sized cells in the CD4+
population in each culture.
Radiographic Studies
Prior to entry into the study, tuberculosis patients had to have a
posterior-anterior and lateral chest x-ray to evaluate for the
presence of cavities. At randomization and 4 months, each
participant had a chest CT-scan at the Groote Schuur Hospital
using a Somatom Balance apparatus (Siemens Medical, Ehrlan-
gen, Germany) and a single breathhold technique. The collimator
was set at 3 mm standard cuts from the superior margin of the
clavicles to the adrenal glands. The standard reconstruction
algorithm was used for soft tissue and high frequency filter for the
lung. The internal volume of each cavity was assessed using
internal cross-sectional diameters.
Statistical Analysis
The analysis, which included all 89 randomized and eligible
subjects, was performed according to the intention-to-treat principle.
Summary statistics (mean, median, standard deviation, and
frequency distribution) were generated for baseline demographics
and clinical presentations to characterize the study population. To
compare the baseline characteristics between 3 treatment groups,
one-way ANOVA or Kruskal-Wallis test was used for continuous
variables, and Chi-square or Fisher’s exact tests, for categorical
variables (Table 1). The primary endpoint of the study was the time
to smear conversion and culture conversion. Kaplan Meier curves
were generated for the time to smear conversion by treatment
groups. The log-rank test was used to compare the Kaplan Meier
curves before 4 weeks. The analysis of culture conversion was done
inthesameway.Forthechangeofsymptomat4weeks,weaveraged
the results from the 3rd, 4th and 5th week data for each subject, and
used one-way ANOVA and two sample t-test for 3 group and two
group comparisons, respectively. For the analysis of cell differentials
in BAL, functional assays, and cavity sizes, the paired t–test or
Wilcoxon signed rank test was used to evaluate the change from
baselineto16weekswithin eachtreatmentgroup (Table2),and one-
wayANOVAorKruskal-Wallistestwasusedtocomparethechange
from baseline to 16 weeks between treatment groups, as appropriate
(Table 3). No adjustment for multiple comparisons was used and no
missing data were imputed. All tests were two sided and p-values less
than 5% were considered statistically significant. All analyses were
conducted using SAS software.
Results
Demographics
There were 96 patients who were randomized and 89 who were
eligible for the study. 10 patients did not complete the trial
including 4 patients who were lost to follow-up, 2 who withdrew
consent, and 4 who were withdrawn due to serious adverse events
(SAE’s): 2 hepatitis, 1 community acquired pneumonia, 1 hypoxia.
Also 1 died from massive hemoptysis, and 1 died in a domestic
accident (the SAE occurred after 16 weeks but before the end of
their DOTS so were left in the analysis, Figure 1). The SAE’s were
not thought to be treatment-related based on Data Safety
Management Board review although the hypoxia in the patient
with emphysema occurred during the bronchoscopy and the
procedure was terminated.
The mean age of the tuberculosis patients who were eligible for
the study ranged from 32–35 years and did not differ among groups
(Table 1). The 3 groups were closely matched for gender (63% to
81%male),andrace(56–63%mixed)and symptoms.Eightypercent
Interferon-c and TB
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infected with HIV-1 and their mean CD4+ was 253 cells/mL( a l l
with CD4+.200 and randomized to DOTS 2, DOTS plus
subcutaneous 1 and nebulized 3. At baseline, the three groups were
comparable in respiratory and constitutional symptoms (Table 1).
Bronchoalveolar lavage
There was a significant increase in median percent lymphocytes
from baseline to 16 weeks in two of three groups in BAL (Table 2;
DOTS 4% to 15%; rIFN-c1b-SC 6% to 22%; rIFN-c1b-NEB 5%
to 15%, p,0.01 for DOTS and rIFN-c1b-SC). There was no
change in lymphocytes/ml BALF recovered. There was a
significant decrease in median percent neutrophils from baseline
to 16 weeks in all three groups in BAL (Table 2; DOTS 28% to
11%; rIFN-c1b-SC 30% to 2%; rIFN-c1b-NEB 24% to 4%), and
a remarkable decline in neutrophils/ml BALF recovered in all 3
groups (DOTS 3.98 to 0.30610
4; rIFN-c1b-SC 3.59 to 0.23610
4;
rIFN-c1b-NEB 2.10 to 0.26610
4). The percentage of macrophag-
es increased slightly over the 16 weeks in all 3 groups. However,
the macrophages/ml decreased 2-fold in all three groups (Table 2).
Functional Assays
There was a significant decline in inflammatory cytokines in
24 hour BAL supernatants in the nebulized rIFN-c1b group only
Table 2. Bronchoalveolar Lavage Results.
% Cells/ml BAL Recovered (10e4)
DOTS Lymphocytes Macrophages Neutrophils Lymphocytes Macrophages Neutrophils
Week 0 4 (2,8) 60 (17,84) 28 (10,82) 0.75 (0.26,1.50) 7.80 (2.58,12.75) 3.98 (0.96, 20.7)
Week 16 15 (6,25) 64 (44,72) 11 (3,31) 0.63 (0.40,1.20) 2.60 (1.98,4.68) 0.03 (0.12,2.00)
p-value ,0.01 0.13 0.01 0.90 0.09 ,0.01
NEBULIZED rIFN-c
Week 0 5 (3,15) 60 (32,80) 24 (5,56) 0.84 (0.30,2.17) 7.43 (4.80,10.64) 2.10 (0.67,11.20)
Week 16 15 (8,34) 63 (40,84) 4 (2,16) 0.80 (0.52,1.60) 3.64 (1.98,7.20) 0.26 (0.14,0.82)
p-value 0.11 0.42 0.05 0.68 0.46 0.04
SUBCUTANEOUS rIFN-c
Week 0 6 (3,10) 62 (43,83) 30 (4,54) 0.56 (0.29,1.86) 7.26 (3.47,17.76) 3.59 (0.60,13.60)
Week 16 22 (13,33) 66 (54,77) 2 (2,9) 1.32 (0.58,3.22) 3.63 (1.90,6.50) 0.23 (0.08,0.52)
p-value ,0.01 0.94 0.02 0.09 ,0.01 ,0.01
*median (25–75 percentile).
doi:10.1371/journal.pone.0006984.t002
Table 1. Baseline Table for Demographic Characteristics for the Three Arms.
DOTS NEBULIZED-rIFN-c SUBCUTANEOUS-rIFN-c p-value
N 30 32 27
Age years+/2SD 32+/211 34+/210 35+/213 0.55
Gender
Female 37% 25% 19% 0.29
Male 63% 75% 81%
Race
Black 37% 41% 37% 0.73
More than one 63% 56% 63%
Asian/white 0% 3% 0%
Cough 96% 100% 100% 0.64
Dyspnea=(2,3) 93% 94% 92% 0.83
Fever (oral T) 46% 35% 42% 0.69
Poor Appetite 29% 45% 50% 0.24
Wheeze 68% 58% 54% 0.55
Weakness 50% 65% 62% 0.50
Tiredness 86% 77% 92% 0.29
Night sweats (Nights/week) 3.8+/22.7 3.0+/22.7 3.2+/23.1 0.54
Sputum Vol ,10 ml 29% 16% 12% 0.25
WeightKg+/2SD 54+/295 6 +/210 55+/27 0.71
doi:10.1371/journal.pone.0006984.t001
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(p=0.02), and IL-10 (p=0.02) (Figure 2).
Peripheral blood lymphocytes showed a significant 2.8-fold
increase in Th1 proliferation when stimulated with PPD but not
SEB or MUMPS in vitro (Figure 3 and Table 3), demonstrating an
enhanced antigen-specific systemic response after one month of
both nebulized and subcutaneous rIFN-c1b administration.
Chest radiology
There was a striking improvement in cavity size as assessed by
HRCT in all 3 groups between baseline and 16 weeks; however,
the rIFN-c1b groups did not differ from DOTS alone (Cavity in
mm: DOTS 34+/211 to 20+/216; rIFN-c1b-SC 39+/224 to
29+/224; rIFN-c1b-NEB 34+/213 to 18+/217.
Sputum Smear Conversion and Change in Symptoms
At 4 weeks, there was a significantly higher smear conversion rate
in the nebulized rIFN-c1b group compared to the DOTS control
andsubcutaneousrIFN-c1bplusDOTSgroups(60%versus36%at
4 weeks, p=0.03 for comparing Kaplan-Meier curves before 4
weeks, Figure 4A). A higher culture conversion rate at 4 weeks was
also observed in the nebulized group compared to DOTS control
and subcutaneous rIFN-c1b plus DOTS (32% vs 18% at 4 weeks,
p=0.15). There was a significant reduction in fever in both rIFN-
c1bgroupscomparedtocontrolDOTSat4and8weeks(Figure4B)
and complaints of night sweats at 4 weeks in both rIFN-c1b groups
compared to DOTS control. Also, there was a significant reduction
in the proportion with wheeze in both IFN-c1b groups at 4, 8, and
12 weeks compared to DOTS control. In addition, at 12 weeks
there was a significant reduction in cough in the groups receiving
rIFN-c1b compared to DOTS control. There was no statistically
significant difference between treatment arms in the incidence of
tiredness, poorappetite,sputumvolume, ordyspnea.Therewasone
treatment failure at 12 months in the DOTS alone group.
Discussion
Immunoadjunctive therapy with nebulized rIFN-c1b plus
DOTS significantly reduced lung inflammatory cytokines in
BAL supernatants at the 16 week time point. We treated five
multiple-drug resistant tuberculosis patients with nebulized rIFN-
c1b while continuing their failing second-line regimens at a dose of
Figure 1. Flow Diagram showing number of study subjects screened, randomized to the three study groups n=96, and who met
inclusion criteria, n=89). 10 patients did not complete the trial including 4 patients who were lost to follow-up, 2 who withdrew consent, and 4
who were withdrawn due to serious adverse events (SAE’s): 2 hepatitis, 1 community acquired pneumonia, 1 hypoxia, 1 who died from massive
hemoptysis, and 1 died in a domestic accident two weeks before the end of the trial (the last two occurred after 16 weeks but before the end of their
DOTS so were left in the analysis).
doi:10.1371/journal.pone.0006984.g001
Table 3. Proliferative Indices of CD4+ peripheral blood
lymphocytes from cavitary TB patients after 3–5 weeks of
treatment.
Treatment N SEB MUMPS PPD
DOTS alone 17 70.263.4 1.661.1 3.260.6
DOTS+ Nebulized IFN-c 19 68.864.8 0.760.2 9.162.6
p, DOTS vs DOTS+ Nebulized IFN-c 0.825 0.475 0.041
DOTS+ Subcutaneous IFN-c 18 65.963.0 0.760.2 9.162.2
p, DOTS vs DOTS+ Subcutaneous IFN-c 0.359 0.444 0.017
Proliferation indices (mean6SEM) were determined by flow cytometry (Fig. 3)
following in vitro stimulation for 5 days with a T cell mitogen (SEB), Mumps
antigen, or PPD at pretitered concentrations. Values given are those determined
in the presence of antigen less that determined in the absence of antigen for
the same specimen. The proliferation index in the absence of antigen was
0.260.4 for all specimens (N=54). Significance p was determined using
unpaired t tests at 95% confidence interval.
doi:10.1371/journal.pone.0006984.t003
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the sputum converted to negative, and symptoms improved. In
order to investigate the mechanisms of these responses, we used
nebulized rIFN-c1b in eleven drug-sensitive tuberculosis patients,
and found an increase in signaling molecules STAT-1, IRF-1 and
IRF-9 [14]. In addition, nebulized rIFN-c1b induced IP-10
downstream from these signaling molecules, but not inducible
nitric oxide synthase (iNOS) [15]. There was a recruitment of
lymphocytes and reduction in the neutrophil inflammation in the
lung in all three groups, which manifested clinically as a dramatic
resolution of the macrophage-neutrophilic alveolitis in the lower
respiratory tract. Concomitantly with the increase in BAL
lymphocytes, blood CD4+ cells doubled in their proliferative
capacity to PPD or Mtb culture filtrate protein stimulation (data
not shown) at the 4 week time point in both immunoadjunctive
rIFN-c1b groups of drug-sensitive pulmonary tuberculosis.
Immunoadjunctive therapy cleared M tuberculosis from the
sputum and resolved the classic symptoms of fever, night sweats,
wheeze, cough and malaise more rapidly than treatment with
either DOTS or DOTS plus subcutaneous rIFN-c1b. This finding
suggests that nebulized rIFN-c1b could reduce transmission due to
more rapid clearance of M tuberculosis during the first 4 weeks. The
subcutaneous rIFN-c1b plus DOTS was not different from control
since only nebulized rIFN-c reaches the lower respiratory tract in
pharmacological amounts to have a biological effect. All treatment
groups experienced radiographic improvement with resolution of
cavities by 16 weeks. Limitations of the study include the fact that
this was an open-label, unblinded study without a placebo, and
there was no group with rIFN-c1b alone.
At 12 months there was only one study subject who had a treatment
failure with culture positive sputum, and this occurred in the DOTS
only control arm. TB Trials Consortium Study 22 comparing
rifapentene and isoniazid once a week versus rifampicin and isoniazid
twice a week reported bilateral pulmonary involvement and cavitation
on chest radiograph were two risk factors (out of five) for treatment
failure/relapse that occurred in 74/1004 (14.9%) of the TB patients
[7]. Although our numbers were much smaller, we had no treatment
failures/relapses among the adjunctive rIFN-c1b groups.
This is the first major report on the efficacy of rIFN-c1b in a
randomized clinical trial. In the first study of nebulized versus
subcutaneous rIFN-c in humans, IP-10 mRNA was detected in
BALcellsonlyinthenebulizedpatientsandnot subcutaneousrIFN-
c treated subjects [16]. This probably explains our finding that only
nebulized rIFN-c1b and not subcutaneous rIFN-c1b was successful
in clearing the sputum of Mtb and reducing the spontaneous release
of inflammatory cytokines in 24 hour BAL supernatants. A pilot
study ofintramuscular rIFN-c plussecond-line anti-TB drugs over a
6-month period in 8 MDR-TB patients from Cuba showed sputum
conversion over 1–3 months and marked improvement of
radiographic abnormalities [17]. Giosue and colleagues nebulized
IFN-a, a type I interferon, for 2 months as an adjunct in a
randomized controlled clinical trial in 20 drug sensitive tuberculosis
patients[18].ImprovementsinMtb numberinthesputumat7 days,
reduced fever by 7 days, reduced number of nodules and area of
consolidation on CT-scans at 2 months, and significant decreases in
BAL fluid amounts at 2 months of IL-1b, IL-6, and TNF-a were
noted in the IFN-a group [18]. In a clinical trial of interleukin-2
adjunctive therapy performed in Uganda, 110 TB patients were
randomized to IL-2 subcutaneously twice/day for the first 30 days
in addition to DOTS versus DOTS alone. Seventeen percent versus
30% sputum conversion, respectively, was observed at 4 weeks [19].
Tramontana and colleagues conducted a clinical trial of thalido-
mide in TB patients blocking TNF-a leading to enhanced weight
gain and increased serum IFN-c in vivo [20].
Figure 2. Reduction in inflammatory cytokines in 24 hour BAL supernatants by nebulized rIFN-c1b comparing baseline to 16 weeks
in ng/ml. A). IL-1b. DOTS or SC rIFN-c plus DOTS, NS; NEB rIFN-c1b plus DOTS, p,0.001. B). IL-6. DOTS or SC rIFN-c plus DOTS, NS; NEB rIFN-c1b plus
DOTS, p,0.04. C). IL-8. DOTS or SC rIFN-c plus DOTS, NS; NEB rIFN-c1b plus DOTS, p,0.02. D). IL-10. DOTS or rIFN-c plus DOTS, NS; NEB rIFN-c1b plus
DOTS, p,0.02.
doi:10.1371/journal.pone.0006984.g002
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elevated cytokine IL-1b, adhesion molecule ICAM, TGF-b,
apoptosis genes, and IFN-c pathway genes [21]. Immunohisto-
chemistry of Mtb-laden lungs show increased IFN-c, IL-12, IP-10,
and TGF-b in granulomas and areas with pneumonitis with
reductions in IL-10 and IL-4 compared to controls [22]. BAL in
Brazilian TB patients shows increased mRNA for TGF-bRI and II
and IL-10 with increased protein for IFN-c, IL-10, and bioactive
TGF-b suggesting that TB has both stimulatory and counter-
regulatory molecules that may ultimately down-regulate the Th1
response [23]. Th2 cytokines may be inhibited by antagonists such
as IL-4d2 that may be increased in TB [24]. PBMC responses
from TB patients to Mtb in vitro are reduced, probably due to IL-
10 which was increased in BAL cell supernatants. Gold and
colleagues have reported low levels of Surfactant Protein A in BAL
from involved segments of active TB along with increased IL-6,
and reduced inhibitory C/EBPb [25].
We noted that BAL lymphocytes increased in all three groups
after 4 months of therapy. Mtb is suppressive of the T cell immune
response, e.g. IFN-c response to PPD-stimulated PBMC is
depressed and TGF-b and IL-10 are increased at the beginning
of TB treatment and return to normal levels only at the end of
treatment 6–9 months later [26,27]. In Gambian TB patients, T
cell response to PPD from blood or pleural fluid was impaired pre-
treatment, that changed to IFN-c release after successful treatment
or IL-4 after treatment failure; addition of IFN-a or IL-12 in vitro
pre-treatment could alter the response to Th1 suggesting that
immunotherapy could increase host defense against mycobacteria
[28]. We showed significantly increased PBMC proliferative
capacity to PPD in the nebulized and subcutaneous rIFN-c1b
groups within 3–5 weeks of immunoadjunctive therapy.
Inflammatory cytokines IL-1b, IL-6, IL-8, IFN-c and TNF-a as
well as anti-inflammatory cytokines IL-10 and TGF-b (and its
TGF-bRI and RII) are elevated in BAL from active TB patients
[29]. The inflammatory response in the lung in TB may include an
increase in neutrophils, particularly in radiographically abnormal
areas. Zhang and colleagues have previously reported that Mtb
and its cell wall components stimulated IL-8 protein release and
mRNA expression in vitro from alveolar macrophages [30]. In
summary, the addition of nebulized recombinant interferon-c1b to
DOTS in a randomized, controlled clinical trial resulted in
reduced BAL cytokines, more rapid clearance of Mtb from the
sputum, improved symptoms, and reduced inflammatory macro-
phage-neutrophil alveolitis. These findings suggest that nebulized
recombinant interferon-c1b may have a role in adjunctive
immune stimulation in patients with cavitary tuberculosis.
Supporting Information
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0006984.s001 (0.04 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0006984.s002 (0.36 MB
DOC)
Figure 3. Detection of the CD4+ Proliferative Response from a Representative Patient. Peripheral blood mononuclear cells were cultured
for 5 days, and pulsed with BrDU during the last 24 hr. Viable cells were labeled with PerCP-anti-CD4 and PE-anti-CD25, permeabilized and reacted
with FITC-anti-BrDU in the presence of DNase, fixed and analyzed by FACS. (A) Lymphoblasts [R2] were discriminated from resting lymphocytes [R1]
by forward and 90u angle (side) scattered laser light. Debris and necrotic cells are indicated by arrowheads. % lymphoblasts were given by the
number of R2 cells divided by the number of R1+R2 cells. Approximately 10,000 events are shown in each dot blot. (B) CD4 intensity on R2 cells [R4]
was used to select for CD4+ lymphoblasts. (C) Proliferating lymphoblasts which are displayed as green dots in (A). A total of 600
doi:10.1371/journal.pone.0006984.g003
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